BRPI0920069A8 - Biomarcadores - Google Patents

Biomarcadores

Info

Publication number
BRPI0920069A8
BRPI0920069A8 BRPI0920069A BRPI0920069A BRPI0920069A8 BR PI0920069 A8 BRPI0920069 A8 BR PI0920069A8 BR PI0920069 A BRPI0920069 A BR PI0920069A BR PI0920069 A BRPI0920069 A BR PI0920069A BR PI0920069 A8 BRPI0920069 A8 BR PI0920069A8
Authority
BR
Brazil
Prior art keywords
biomarkers
suffered
myocardial infarction
increased risk
identifying patients
Prior art date
Application number
BRPI0920069A
Other languages
English (en)
Portuguese (pt)
Inventor
Devaux Yvan
R Wagner Daniel
Azuaje Francisco
Vausort Mélanie
Original Assignee
Centre De Rech Public De La Sante
Luxembourg Inst Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre De Rech Public De La Sante, Luxembourg Inst Of Health filed Critical Centre De Rech Public De La Sante
Publication of BRPI0920069A2 publication Critical patent/BRPI0920069A2/pt
Publication of BRPI0920069A8 publication Critical patent/BRPI0920069A8/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0920069A 2008-10-30 2009-10-30 Biomarcadores BRPI0920069A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10964908P 2008-10-30 2008-10-30
PCT/EP2009/064410 WO2010049538A1 (en) 2008-10-30 2009-10-30 Biomarkers

Publications (2)

Publication Number Publication Date
BRPI0920069A2 BRPI0920069A2 (pt) 2017-06-06
BRPI0920069A8 true BRPI0920069A8 (pt) 2017-10-03

Family

ID=41528764

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920069A BRPI0920069A8 (pt) 2008-10-30 2009-10-30 Biomarcadores

Country Status (9)

Country Link
US (2) US20110294683A1 (enExample)
EP (1) EP2362942B1 (enExample)
JP (1) JP5749171B2 (enExample)
CN (1) CN102203606A (enExample)
BR (1) BRPI0920069A8 (enExample)
CA (1) CA2741117A1 (enExample)
ES (1) ES2640900T3 (enExample)
RU (1) RU2545757C2 (enExample)
WO (1) WO2010049538A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5905003B2 (ja) 2010-07-09 2016-04-20 ソマロジック・インコーポレーテッド 肺癌バイオマーカーとその使用
MX350533B (es) 2010-08-13 2017-09-08 Somalogic Inc Biomarcadores de cancer pancreatico y usos de los mismos.
EP2592422A1 (en) * 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
JP2014207883A (ja) * 2013-03-27 2014-11-06 国立大学法人岡山大学 がん幹細胞及びその用途
WO2014191553A2 (en) * 2013-05-31 2014-12-04 Cobiores Nv Heart failure treatment
EP2843414B1 (en) 2013-08-26 2018-09-19 Roche Diagniostics GmbH Marker for statin treatment stratification in heart failure
CN103487586B (zh) * 2013-09-04 2015-07-15 石家庄洹众生物科技有限公司 一种定量检测可溶性生长刺激表达蛋白2的试验装置
PL228091B1 (pl) * 2014-02-12 2018-02-28 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro
WO2015183601A1 (en) * 2014-05-28 2015-12-03 Scripps Health Predictive analysis for myocardial infarction
CN105243294B (zh) * 2015-09-18 2017-06-09 淮南师范学院 一种用于预测癌症病人预后相关的蛋白质对的方法
RU2634375C2 (ru) * 2016-04-18 2017-10-26 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт кардиологии" Способ предупреждения постинфарктного ремоделирования сердца в эксперименте
EP4322168A3 (en) * 2016-07-06 2024-05-15 Guardant Health, Inc. Methods for fragmentome profiling of cell-free nucleic acids
DE102017116204B4 (de) * 2017-07-18 2024-06-27 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration
US11708600B2 (en) * 2017-10-05 2023-07-25 Decode Health, Inc. Long non-coding RNA gene expression signatures in disease diagnosis
JP2022549479A (ja) * 2019-09-30 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー 疾患状態の予測方法
JP7489059B2 (ja) * 2020-04-21 2024-05-23 国立大学法人横浜国立大学 画像生成装置、表示装置、画像生成方法、提示方法およびプログラム
US11854675B1 (en) 2022-10-11 2023-12-26 Flatiron Health, Inc. Machine learning extraction of clinical variable values for subjects from clinical record data
US11915807B1 (en) * 2022-10-11 2024-02-27 Flatiron Health, Inc. Machine learning extraction of clinical variable values for subjects from clinical record data

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052462A1 (en) * 1999-03-03 2000-09-08 Ludwig Institute For Cancer Research Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities
CN1260492A (zh) * 1999-11-09 2000-07-19 赵永同 肿瘤预后评估试剂盒及其制备工艺
CN1139811C (zh) * 1999-11-09 2004-02-25 赵永同 肿瘤早期检测评估试剂盒及其制备工艺
AU774575C (en) * 1999-11-16 2005-09-08 Genentech Inc. Elisa for VEGF
NZ522014A (en) * 2000-05-17 2007-03-30 Ludwig Inst Cancer Res Methods for detecting for the presence of tumor cells and for screening for anti-tumor agents
NZ529915A (en) * 2001-06-20 2007-07-27 Ludwig Inst Cancer Res Stimulation of vascularization of ischemic tissue by angiogenesis with VEGF-B186
AU2002356033A1 (en) * 2001-08-13 2003-03-03 Genetics Development Corporation A molecular diagnostic and computerized decision support system for selecting the optimum treatment for human cancer
US20030096248A1 (en) * 2001-09-04 2003-05-22 Vitivity, Inc. Diagnosis and treatment of vascular disease
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
JP4741249B2 (ja) * 2002-11-16 2011-08-03 シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー 心血管疾患における生化学的マーカーの組合せとしてのｓＣＤ４０Ｌ，ＰＡＰＰ−Ａおよび胎盤増殖因子（ＰｌＧＦ）
US8632994B2 (en) * 2003-12-01 2014-01-21 Dako Denmark A/S Methods and compositions for immuno-histochemical detection
EP1968565B1 (en) * 2004-04-16 2015-11-18 Sun Baocun Compositions and methods for inhibiting angiogenesis
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use

Also Published As

Publication number Publication date
US20160188835A1 (en) 2016-06-30
BRPI0920069A2 (pt) 2017-06-06
WO2010049538A1 (en) 2010-05-06
JP2012507026A (ja) 2012-03-22
US20110294683A1 (en) 2011-12-01
JP5749171B2 (ja) 2015-07-15
ES2640900T3 (es) 2017-11-07
CA2741117A1 (en) 2010-05-06
EP2362942A1 (en) 2011-09-07
EP2362942B1 (en) 2017-06-21
RU2545757C2 (ru) 2015-04-10
CN102203606A (zh) 2011-09-28
RU2011121613A (ru) 2012-12-10

Similar Documents

Publication Publication Date Title
BRPI0920069A8 (pt) Biomarcadores
MX2015015605A (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
MX358541B (es) Metodos para predecir el riesgo de desarrollar hipertension.
MX391175B (es) Macrociclos peptidomimeticos.
CL2012002741A1 (es) Metodo para determinar en una muestra de sangre la presencia de vitamina d libre; inmunoensayo para detrminar presencia de vitamina d libre en sangre; kit para efectuar inmunoensayo.
BR112012031389A2 (pt) método para prever os resultados clínicos para pacientes com melanoma usando células de melanoma circulantes no sangue
AR077026A1 (es) Marcadores de riesgo para enfermedades cardiovasculares
CR20110066A (es) Anticuerpos monoclonales contra el factor tisular inhibidor de la via
MX2013002372A (es) Metodos para recelularizar un tejido o un organo para una transplantabilidad mejorada.
BR112012012513A2 (pt) método para diagnosticar síndrome do intestino irritável em um paciente, método para monitorar a progressão ou regressão da síndrome do intestino irritável em um paciente, e para designar uma terapia contra síndrome do intestino irritável a um paciente em necessidade do mesmo
ES2654340T3 (es) Marcadores para cáncer endometrial
ZA201104357B (en) Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
EP3546939A3 (en) An assay for measuring cell-mediated immunoresponsiveness
EA201590024A1 (ru) Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
BRPI0820557A2 (pt) biomarcadores diagnósticos de diabetes
BR112013009970A2 (pt) método para determinar uma característica do ritmo circadiano de um paciente.
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
EP2185174A4 (en) METHOD OF USE OF TRIM72 AS A TARGET FOR MUSCLE AND HEART ENHANCER
ES2679289T3 (es) Procedimientos para el pronóstico y/o diagnóstico de una enfermedad neurodegenerativa, procedimientos para identificar compuestos candidatos y compuestos para tratar una enfermedad neurodegenerativa
BR112012032389A2 (pt) biomarcadores para a previsão de câncer incidente
MX377026B (es) Biomarcadores para la progresión de enfermedades en melanoma.
BR112014009223A2 (pt) método para o diagnóstico da doença de niemann-pick
FR2936255B1 (fr) Modulateurs de fzd2 dans le traitement de l'alopecie
BR112013031431A2 (pt) método para o diagnóstico da doença de gaucher
EP2920595A4 (en) METHOD FOR DIAGNOSIS OF CANCER AND ENZYME-LINKED IMMUNOASSAY (ELISA) KIT THEREFOR

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: LUXEMBOURG INSTITUTE OF HEALTH (LU)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2486 DE 28-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.